Technology ID

Intranasal Dry Powder Inhaler for Improved Delivery of Vaccines and Therapeutics

Lead Inventor
Papania, Mark (CDC)
Barry, James (CDC)
Knaus, Darin (CDC)
Moynihan, Edward (CDC)
Friets, Eric (CDC)
Bagley, Mark (CDC)
Non-Medical Devices
Medical Devices
Consumer Products
Therapeutic Areas
Infectious Disease
Development Stages
Pre-Clinical (in vitro)
Development Status
  • In vitro data available
  • Prototype
Lead IC
This Intranasal Dry Powder Inhaler (DPI), developed with Creare, Inc., allows low-cost delivery of powder vaccines. Nasal delivery has numerous advantages compared to traditional injected vaccines, including: 1) safe, needle-less administration by minimally-trained staff or patient; 2) better protection due to mucosal and cross-protection; and 3) decreased biohazard waste. Further, dry powder aerosol vaccine delivery is superior to liquid aerosol delivery in a number of ways, including: 1) no dose reconstitution required; 2) highly thermostable and may not need cold chain storage; 3) costs less to store and transport; 4) improved efficacy through elimination of liquid spray nasal-dripping. This CDC-Creare invention is unique in that it is inexpensive and suitable for single-use applications, such as vaccination. It prevents the dose being deposited within the lower respiratory tract, improving safety. This delivery system has a broad range of potential applications including, but not limited to, childhood vaccination programs, self-administered therapeutics, and emergency biodefense.
Commercial Applications
  • Intranasal delivery of vaccines and therapeutics
  • Childhood vaccination programs, mass immunization campaigns, or response to epidemics
Competitive Advantages
  • Safe, needle-less delivery
  • Allows self-administration
  • Improved protection via intranasal immunization
  • Decreased biohazard waste
  • Dose reconstitution is not required
  • Highly thermostable and may not need cold chain storage
  • Cost-effective
  • Primate study with a thermostable measles vaccine expected in the next year
Licensing Contact:
Mitzelfelt, Jeremiah